Please login to the form below
Merck and Co.
This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda combination granted FDA approval for biliary tract cancer
Merck &Co – known as MSD outside the US and Canada – has announced that the US Food and Drug Administration (FDA) has approved its anti-PD-1 therapy Keytruda (pembrolizumab) in combination ... Dr Marjorie Green, senior vice president and head of
Latest news
-
Merck’s Keytruda granted FDA approval for expanded use in lung cancer
Merck &Co – known as MSD outside the US and Canada – has announced that the US Food and Drug Administration (FDA) has approved its anti-PD-1 therapy Keytruda (pembrolizumab) to treat ... There are also currently more than 1, 600 trials studying the
-
EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia
AML is a rapidly progressing cancer of the blood and bone marrow and the most common form of acute leukaemia in adults. ... The EC approval comes just over a month after Astex and MSD – known as Merck &Co in the US and Canada – expanded their drug
-
Novartis sues US government over Medicare drug price negotiation programme
Other drugs selected for negotiation were Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and Boehringer ... The plan is facing court
-
US government announces first ten drugs subject to Medicare pricing negotiations
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and ... However, the
-
AstraZeneca latest to sue US government over Medicare drug price negotiation plan
The plan already faces at least seven court challenges from leading drugmakers and industry groups, including Merck &Co, Bristol Myers Squibb, Johnson &Johnson, Boehringer Ingelheim and the Pharmaceutical Research and Manufacturers ... Rare disease and
More from news
Approximately 44 fully matching, plus 542 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
-
Vertex: a vision of treating all CF patients worldwide draws closer
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Latest appointments
-
Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
Arnhofer joins the agency with two decades of experience in the biopharma industry, having held a variety of senior positions at Merck &Co, Bayer AG and BioNTech SE. ... Storyteq marketing collaboration and creative automation platform, in addition to
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Weekly industry appointments
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
-
Nabriva Therapeutics appoints chief medical officer
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
-
Hansa Medical poaches Vifor Pharma’s CEO
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Practical Patient Centricity
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
-
Digital Marketing is no Substitute for Sound Strategic Marketing
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
